Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

2.

Cooperative binding and activation of fibronectin by a bacterial surface protein.

Marjenberg ZR, Ellis IR, Hagan RM, Prabhakaran S, Höök M, Talay SR, Potts JR, Staunton D, Schwarz-Linek U.

J Biol Chem. 2011 Jan 21;286(3):1884-94. doi: 10.1074/jbc.M110.183053. Epub 2010 Nov 8.

3.

NMR spectroscopic and theoretical analysis of a spontaneously formed Lys-Asp isopeptide bond.

Hagan RM, Björnsson R, McMahon SA, Schomburg B, Braithwaite V, Bühl M, Naismith JH, Schwarz-Linek U.

Angew Chem Int Ed Engl. 2010 Nov 2;49(45):8421-5. doi: 10.1002/anie.201004340. No abstract available.

4.

Natural ligand binding and transfer from liver fatty acid binding protein (LFABP) to membranes.

De Gerónimo E, Hagan RM, Wilton DC, Córsico B.

Biochim Biophys Acta. 2010 Sep;1801(9):1082-9. doi: 10.1016/j.bbalip.2010.05.008. Epub 2010 Jun 10.

PMID:
20541621
5.

BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.

Maubach KA, Davis RJ, Clark DE, Fenton G, Lockey PM, Clark KL, Oxford AW, Hagan RM, Routledge C, Coleman RA.

Br J Pharmacol. 2009 Jan;156(2):316-27. doi: 10.1111/j.1476-5381.2009.00027.x. Epub 2009 Jan 19.

7.

Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo.

Southam E, Pereira R, Stratton SC, Sargent R, Ford AJ, Butterfield LJ, Wheable JD, Beckett SR, Roe C, Marsden CA, Hagan RM.

Eur J Pharmacol. 2005 Sep 20;519(3):237-45.

PMID:
16129425
8.
9.

Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model.

Stratton SC, Large CH, Cox B, Davies G, Hagan RM.

Epilepsy Res. 2003 Feb;53(1-2):95-106.

PMID:
12576171
11.

Effect of charge reversal mutations on the ligand- and membrane-binding properties of liver fatty acid-binding protein.

Davies JK, Hagan RM, Wilton DC.

J Biol Chem. 2002 Dec 13;277(50):48395-402. Epub 2002 Oct 11.

12.

Broad spectrum anticonvulsant activity of BW534U87: possible role of an adenosine-dependent mechanism.

Southam E, Stratton SC, Sargent RS, Brackenborough KT, Duffy C, Hagan RM, Pratt GD, Jones SA, Morgan PF.

Pharmacol Biochem Behav. 2002 Dec;74(1):111-8.

PMID:
12376158
14.

Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude.

Drijfhout WJ, de Vries JB, Homan EJ, Brons HF, Copinga S, Gruppen G, Beresford IJ, Hagan RM, Grol CJ, Westerink BH.

Eur J Pharmacol. 1999 Oct 15;382(3):157-66.

PMID:
10556666
15.

Identification of two novel diurnal genes by screening of a rat brain cDNA library.

Patten C, Clayton CL, Blakemore SJ, Trower MK, Wallace DM, Hagan RM.

Neuroreport. 1999 Apr 6;10(5):1155-61.

PMID:
10321501
16.

Identification of two novel diurnal genes by screening of a rat brain cDNA library.

Patten C, Clayton CL, Blakemore SJ, Trower MK, Wallace DM, Hagan RM.

Neuroreport. 1998 Dec 1;9(17):3935-41.

PMID:
9875732
17.

Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats.

Southam E, Kirkby D, Higgins GA, Hagan RM.

Eur J Pharmacol. 1998 Sep 25;358(1):19-24.

PMID:
9809864
18.

Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder.

Xie X, Hagan RM.

Neuropsychobiology. 1998 Oct;38(3):119-30. Review.

PMID:
9778599
19.

GR196429: a nonindolic agonist at high-affinity melatonin receptors.

Beresford IJ, Browning C, Starkey SJ, Brown J, Foord SM, Coughlan J, North PC, Dubocovich ML, Hagan RM.

J Pharmacol Exp Ther. 1998 Jun;285(3):1239-45.

PMID:
9618428
20.

Adenosine A1 receptor agonist GR79236 suppresses apnea during all sleep stages in the rat.

Carley DW, Hagan RM, Sheehan M, Trbovic S, Thai T, Radulovacki M.

Sleep. 1997 Dec;20(12):1093-8.

PMID:
9493917
21.

Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure.

Marshall FH, Stratton SC, Mullings J, Ford E, Worton SP, Oakley NR, Hagan RM.

Pharmacol Biochem Behav. 1997 Sep;58(1):1-8.

PMID:
9264062
22.

A microdialysis study on pineal melatonin rhythms in rats after an 8-h phase advance: new characteristics of the underlying pacemaker.

Drijfhout WJ, Brons HF, Oakley N, Hagan RM, Grol CJ, Westerink BH.

Neuroscience. 1997 Sep;80(1):233-9.

PMID:
9252234
23.

5-HT3 and 5-HT4 receptors in terminal regions of the mesolimbic system.

Kilpatrick GJ, Hagan RM, Gale JD.

Behav Brain Res. 1996;73(1-2):11-3. Review.

PMID:
8788470
24.

Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion.

Hawcock AB, Beresford IJ, Marshall FH, Hagan RM.

Eur J Pharmacol. 1995 Dec 27;294(1):163-71.

PMID:
8788428
25.

The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.

Beattie DT, Beresford IJ, Connor HE, Marshall FH, Hawcock AB, Hagan RM, Bowers J, Birch PJ, Ward P.

Br J Pharmacol. 1995 Dec;116(8):3149-57.

26.

Modulation of the rat suprachiasmatic circadian clock by melatonin in vitro.

Starkey SJ, Walker MP, Beresford IJ, Hagan RM.

Neuroreport. 1995 Oct 2;6(14):1947-51.

PMID:
8547604
27.

The anxiolytic-like activity of GR159897, a non-peptide NK2 receptor antagonist, in rodent and primate models of anxiety.

Walsh DM, Stratton SC, Harvey FJ, Beresford IJ, Hagan RM.

Psychopharmacology (Berl). 1995 Sep;121(2):186-91.

PMID:
8545524
28.

Pharmacological characterization of GR82334, a tachykinin NK1 receptor antagonist, in the isolated spinal cord of the neonatal rat.

Guo JZ, Yoshioka K, Zhao FY, Hosoki R, Maehara T, Yanagisawa M, Hagan RM, Otsuka M.

Eur J Pharmacol. 1995 Jul 25;281(1):49-54.

PMID:
8566116
29.

Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache.

Beattie DT, Connor HE, Hagan RM.

Can J Physiol Pharmacol. 1995 Jul;73(7):871-7. Review.

PMID:
8846424
30.

Melatonin comes of age?

Hagan RM, Oakley NR.

Trends Pharmacol Sci. 1995 Mar;16(3):81-3. Review. No abstract available.

PMID:
7792932
31.

GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors.

Beresford IJ, Sheldrick RL, Ball DI, Turpin MP, Walsh DM, Hawcock AB, Coleman RA, Hagan RM, Tyers MB.

Eur J Pharmacol. 1995 Jan 16;272(2-3):241-8.

PMID:
7713168
32.

GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors.

Stables JM, Beresford IJ, Arkinstall S, Ireland SJ, Walsh DM, Seale PW, Ward P, Hagan RM.

Neuropeptides. 1994 Dec;27(6):333-41.

PMID:
7534879
33.

Anxiolytic activity of tachykinin NK2 receptor antagonists in the mouse light-dark box.

Stratton SC, Beresford IJ, Harvey FJ, Turpin MP, Hagan RM, Tyers MB.

Eur J Pharmacol. 1993 Dec 21;250(3):R11-2.

PMID:
7906655
34.

Synthesis of a potent antagonist of substance P by replacing the CH2SCH3 and the alpha-carboxamide groups of the methionine at [Orn6]-SP6-11 by benzyl ester groups.

Karagiannis K, Stavropoulos G, Poulos C, Jordan CC, Hagan RM.

Int J Pept Protein Res. 1993 Dec;42(6):565-9.

PMID:
7508424
35.

Depression of primary afferent-evoked responses by GR71251 in the isolated spinal cord of the neonatal rat.

Guo JZ, Yoshioka K, Yanagisawa M, Hosoki R, Hagan RM, Otsuka M.

Br J Pharmacol. 1993 Nov;110(3):1142-8.

36.

Pharmacological characteristics of tachykinin receptors mediating acetylcholine release from neonatal rat spinal cord.

Suzuki H, Yoshioka K, Maehara T, Hagan RM, Nakanishi S, Otsuka M.

Eur J Pharmacol. 1993 Sep 7;241(1):105-10.

PMID:
8223920
37.

Vineyard peptide conference bears fruit.

Hagan RM, McLean S.

Trends Pharmacol Sci. 1993 Sep;14(9):315-8. Review. No abstract available.

PMID:
8249150
38.

Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists.

Hagan RM, Beresford IJ, Stables J, Dupere J, Stubbs CM, Elliott PJ, Sheldrick RL, Chollet A, Kawashima E, McElroy AB, et al.

Regul Pept. 1993 Jul 2;46(1-2):9-19. No abstract available.

PMID:
8210508
39.

Blockade of cutaneous nerve-evoked responses by GR71251 in the isolated spinal cord preparation of newborn rat.

Guo JZ, Yoshioka K, Yanagisawa M, Hagan RM, Otsuka M.

Regul Pept. 1993 Jul 2;46(1-2):309-10. No abstract available.

PMID:
7692524
41.

Synthesis of potent antagonists of substance P by modifying the methionyl and glutaminyl residues of its C-terminal hexapeptide and without using D-amino acids.

Manolopoulou A, Karagiannis K, Stavropoulos G, Poulos C, Jordan CC, Hagan RM.

Int J Pept Protein Res. 1993 Apr;41(4):411-4.

PMID:
7684361
42.
43.

Modulation of the rat mesolimbic dopamine pathway by neurokinins.

Elliott PJ, Mason GS, Graham EA, Turpin MP, Hagan RM.

Behav Brain Res. 1992 Oct 31;51(1):77-82.

PMID:
1282818
44.

Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2 receptor agonists.

Deal MJ, Hagan RM, Ireland SJ, Jordan CC, McElroy AB, Porter B, Ross BC, Stephens-Smith M, Ward P.

J Med Chem. 1992 Oct 30;35(22):4195-204.

PMID:
1331460
45.

Highly potent and selective heptapeptide antagonists of the neurokinin NK-2 receptor.

McElroy AB, Clegg SP, Deal MJ, Ewan GB, Hagan RM, Ireland SJ, Jordan CC, Porter B, Ross BC, Ward P, et al.

J Med Chem. 1992 Jul 10;35(14):2582-91.

PMID:
1321907
46.

Neurokinin agonists differentially affect A9 and A10 dopamine cells in the rat.

Overton P, Elliott PJ, Hagan RM, Clark D.

Eur J Pharmacol. 1992 Mar 17;213(1):165-6.

PMID:
1379929
47.

Role of NK-2 receptors in the antidipsogenic activity of neurokinins in the mouse.

Walsh DM, Elliott PJ, Hagan RM.

Gen Pharmacol. 1992 Mar;23(2):231-3.

PMID:
1322337
48.
49.

Synthesis of a potent agonist of substance P by modifying the methionyl and glutaminyl residues of the C-terminal hexapeptide of substance P. Structure-activity relationships.

Karagiannis K, Manolopoulou A, Stavropoulos G, Poulos C, Jordan CC, Hagan RM.

Int J Pept Protein Res. 1991 Oct;38(4):350-6.

PMID:
1724664
50.

Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96,345.

Beresford IJ, Birch PJ, Hagan RM, Ireland SJ.

Br J Pharmacol. 1991 Oct;104(2):292-3.

Supplemental Content

Loading ...
Support Center